Every peptide calculator

A GLP-1 receptor agonist prescribed for type 2 diabetes and chronic weight management, dosed once weekly.

A dual GIP and GLP-1 receptor agonist prescribed for type 2 diabetes and chronic weight management, dosed once weekly.

An investigational triple receptor agonist studied for obesity and metabolic disease. Not available as an approved medicine.

A fragment of human growth hormone originally investigated for obesity, which failed to meet endpoints in clinical trials.

A small-molecule NNMT inhibitor studied for effects on fat cell metabolism. Not a peptide, and not an approved drug.

An investigational peptide designed to destroy the blood vessels feeding white fat. Studied mainly in animals, with early human work halted.

An AMPK activator studied as an 'exercise mimetic.' Not a peptide, prohibited in sport, and not approved for human use.

An investigational long-acting amylin analog for weight management, studied alone and in combination with semaglutide.

The investigational fixed combination of the amylin analog cagrilintide with the GLP-1 agonist semaglutide, developed for greater weight loss.

A naturally occurring compound involved in fat transport into mitochondria, available as an oral supplement and an injectable prescription product.

An investigational dual GLP-1 and glucagon receptor agonist developed for weight management and metabolic disease.

A compounded 'lipotropic' injection blend of nutrients marketed for weight loss. Evidence for meaningful fat loss is weak.

A lipotropic injection blend of methionine, inositol, and choline, often combined with B12 or carnitine. Evidence for weight loss is weak.

A mitochondria-encoded peptide studied for effects on metabolism and insulin sensitivity. Human evidence is early.

An investigational pairing of the triple agonist retatrutide with the amylin analog cagrilintide. No combined product is approved.

An unstandardized supplier blend of retatrutide and tirzepatide. No such combined product is approved or studied.

An investigational dual GLP-1 and glucagon receptor agonist studied for obesity and metabolic liver disease (MASH).

A synthetic 15-amino-acid peptide widely discussed in connection with tissue repair. Human evidence is very limited.

A synthetic fragment related to thymosin beta-4, discussed alongside BPC-157 in repair-focused protocols.

A copper-binding tripeptide common in topical skin and hair formulations, also sold as a lyophilized vial.

A popular unregulated pairing of BPC-157 and TB-500 for tissue repair. Neither component is approved, and the combination is unstudied.

A short 'peptide bioregulator' from the Russian cytomedin tradition, marketed for respiratory support. Evidence is thin and largely non-Western.

A short cartilage-targeted 'peptide bioregulator' marketed for joint support. Evidence is thin and largely regional.

A branded supplier blend, typically combining GHK-Cu with repair peptides like BPC-157 and TB-500. Composition varies by supplier and is unregulated.

A branded supplier blend, typically combining the anti-inflammatory peptide KPV with GHK-Cu and repair peptides. Composition varies and is unregulated.

A tripeptide fragment of alpha-MSH studied for anti-inflammatory effects, particularly in the gut. Human evidence is early.

An immune-modulating peptide approved in some countries for hepatitis and as a vaccine adjuvant, but not in the United States.

A selective growth hormone secretagogue often discussed together with CJC-1295.

A GHRH analog discussed in growth hormone secretagogue protocols, frequently paired with ipamorelin.

A GHRH analog historically used in diagnostic testing and now dispensed largely through compounding pharmacies.

A GHRH analog approved to reduce excess abdominal fat in people with HIV-associated lipodystrophy.

The most common growth-hormone secretagogue pairing, combining a GHRH analog with a ghrelin-mimetic. Neither component is approved; the blend is unregulated.

The long-acting form of CJC-1295, bound to a drug affinity complex that extends its half-life to about a week. Not approved; prohibited in sport.

A protein that binds and neutralizes myostatin, studied for muscle growth. Investigated via gene therapy; peptide use is unstudied and risky.

A ghrelin-mimetic growth hormone secretagogue, one of the earlier and less selective of its class. Not approved; prohibited in sport.

A ghrelin-mimetic growth hormone secretagogue notable for strongly stimulating appetite. Not approved; prohibited in sport.

A potent ghrelin-mimetic growth hormone secretagogue, among the strongest of its class but with receptor desensitization over time. Not approved.

Recombinant human growth hormone — the full 191-amino-acid hormone. A prescription drug for specific deficiency states; widely misused.

A long-acting modified form of IGF-1 studied for anabolic effects. A research compound with no approved use and real hypoglycemia risk.

A truncated, fast-acting form of IGF-1 with reduced binding-protein interference. A research compound with no approved use and hypoglycemia risk.

A splice variant of IGF-1 produced by muscle in response to mechanical damage, studied for muscle repair. No human trials.

A PEGylated (longer-acting) form of mechano growth factor, modified to extend its short half-life. No human trials.

A pairing of the approved GHRH analog tesamorelin with the secretagogue ipamorelin. Tesamorelin alone is approved; the combination is not studied.

A melanocortin receptor agonist approved for hypoactive sexual desire disorder in premenopausal women.

A hormone used medically for fertility and, in men, to stimulate testosterone production. A prescription drug; also misused in sport.

A purified preparation of FSH and LH used for fertility treatment. A prescription drug administered under specialist care.

A peptide that triggers the hormonal cascade leading to reproductive hormone release. Studied in humans for fertility and reproductive function.

A melanocortin agonist approved as an implant for a rare light-sensitivity disorder. Non-approved tanning use is unregulated and risky.

A non-selective melanocortin agonist sold for tanning and libido. Not approved anywhere; unregulated use carries real risks.

A hormone used medically to induce labor and control postpartum bleeding. Also studied for social bonding. A prescription drug for its medical uses.

A long-acting injectable testosterone ester. A controlled substance and prescription drug for diagnosed hypogonadism.

A long-acting injectable testosterone ester. A controlled substance and prescription drug for diagnosed hypogonadism.

A short heart-targeted 'peptide bioregulator' marketed for cardiovascular support. Evidence is thin and largely regional.

A tetrapeptide studied for effects on telomerase and aging markers. Popular in longevity circles, but human evidence is limited and mostly regional.

An investigational 'senolytic' peptide designed to clear senescent (aged) cells. Studied in animals; no human trials.

A synthetic form of GnRH used as a diagnostic agent and to stimulate gonadotropin release. Pulsatile dosing is used for certain fertility indications.

A mitochondria-encoded peptide with cytoprotective effects in animal models, studied for roles in aging and neurodegeneration. No human trials.

A coenzyme central to cellular energy metabolism, supplemented orally (as precursors) and by IV. Levels decline with age. Not a peptide.

A mitochondria-targeted peptide studied in human trials for mitochondrial and heart disease. Investigational, with mixed trial results.

Thymic peptides studied for immune modulation, popular in longevity protocols. Evidence is largely regional; thymulin itself is not available as an approved drug.

A short blood-vessel-targeted 'peptide bioregulator' marketed for vascular support. Evidence is thin and largely regional.

A short thymus-derived 'peptide bioregulator' marketed for immune and longevity support. Evidence is thin and largely regional.

A research peptide marketed for cognitive support. There is no meaningful published evidence base for it.

A supplier-branded research peptide marketed for cognitive support. There is no meaningful published evidence base for it.

A supplier-branded research peptide marketed for cognitive support. There is no meaningful published evidence base for it.

A supplier-branded research peptide containing an adamantane group, marketed for cognitive support. No meaningful published evidence base.

A mixture of peptides derived from pig brain, used in some countries for stroke and dementia. Not approved in the US; evidence is contested.

A brain-derived peptide mixture similar to Cerebrolysin, used in some countries for neurological conditions. Not approved in the US.

A short brain-targeted 'peptide bioregulator' marketed for cognitive support. Evidence is thin and largely regional.

A research peptide derived from angiotensin IV, studied for potent cognitive effects in animal models. Extremely potent; no human trials.

A nonapeptide studied for sleep and stress effects since the 1970s. Evidence for a clear sleep-inducing effect is inconsistent.

A short peptide analog studied for rapid antidepressant-like effects in animal models via TREK-1 channel blockade. No human trials.

A short pineal-gland-targeted 'peptide bioregulator' marketed for sleep and cognitive support. Evidence is thin and largely regional.

A synthetic heptapeptide analog of tuftsin, studied for anxiolytic effects. Used in Russia; not approved in the US.

A pairing of the anxiolytic peptide Selank with the nootropic peptide Semax. Neither is approved in the US; the combination is unstudied.

A synthetic fragment of ACTH studied for nootropic and neuroprotective effects. Used in Russia; not approved in the US.

An investigational myostatin-inhibiting protein developed for muscular dystrophy. Development was halted over safety signals.

A dilute acid solution sometimes used to reconstitute certain peptides that don't dissolve well in plain water. Not a drug.

A copper-binding peptide studied for hair growth and skin, a relative of GHK-Cu. Largely cosmetic and in-vitro evidence.

A prostaglandin used to treat erectile dysfunction and to keep a fetal heart vessel open in newborns. A prescription drug.

A peptide derived from erythropoietin, studied for nerve pain and tissue repair without the blood-thickening effects of EPO. Investigational.

Sterile water with 0.9% benzyl alcohol, used to dissolve and store injectable medications. The standard reconstitution liquid.

A neurotoxin used medically and cosmetically to relax muscles. A prescription drug with strict handling — not a peptide for self-administration.

A short 'peptide bioregulator' marketed for immune support. Evidence is thin and largely regional.

A potent opioid peptide originally from frog skin, with pain-relieving effects stronger than morphine in animals. Abused in horse racing; not for human use.

An investigational next-generation amylin analog for weight management. Early-stage; not approved.

A hormone that stimulates red blood cell production, used to treat certain anemias. A prescription drug with serious risks in misuse.

The scientific name for myostatin — the body's natural brake on muscle growth. Note: myostatin inhibitors are what's studied, not myostatin itself.

The body's main intracellular antioxidant, given by IV and orally for various uses. Oral absorption is poor; IV use is clinical.

A large sugar molecule used in skin fillers, joint injections, and topical products. Approved for specific uses; widely used cosmetically.

A life-sustaining hormone for diabetes. A prescription drug with a narrow safety margin — dosing errors can be fatal.

A supplier-branded research compound. There is no meaningful published evidence base for it.

A supplier-branded research compound. There is no meaningful published evidence base for it.

A human antimicrobial peptide involved in immune defense. Studied for infection and wound healing; complex immune effects, no approved use.

The three-amino-acid sequence that makes up KPV, the anti-inflammatory fragment of alpha-MSH. See the KPV entry for the full picture.

A well-established cosmetic peptide used topically for skin aging. One of the few peptides with real cosmetic-trial support.

An oral growth-hormone secretagogue (not a peptide) studied in human trials. Investigational; raises appetite and blood sugar.

A sterile salt-and-buffer solution used to dissolve and dilute laboratory compounds. Not a drug.

A research peptide studied in the lab for selectively killing cancer cells. Cell and animal work only; no human trials.

A branded supplier blend marketed for relaxation and sleep. Composition varies by supplier and is unregulated.

A research 'exercise mimetic' that activates estrogen-related receptors to mimic exercise metabolism. Animal studies only; not a peptide.

A topical cosmetic peptide marketed as a 'botox-like' anti-wrinkle ingredient. Cosmetic-grade evidence only.

A short testis-targeted 'peptide bioregulator' marketed for male hormonal support. Evidence is thin and largely regional.

A naturally occurring hormone that dilates blood vessels and airways. Studied for pulmonary hypertension and other conditions; investigational for most uses.

The common abbreviation for vasoactive intestinal peptide — a natural hormone that dilates blood vessels and airways. See the full VIP entry.

An essential B vitamin given by injection for deficiency. Not a peptide; well established for treating true deficiency.